Clinical Trial Update: Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial update on ALD518 for reducing oral mucositis in head and neck cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• ALD518

Snippet

Sponsor: CSL Behring | Conditions: Oral Mucositis | Phase 2 | Status: TERMINATED | Results posted: 2021-05-11